Cartas familiares : escritas á su hermana Doña María Francisca de Isla y Losada, y á su cuñado D. Nicolás de Ayala.

Vol. 5 has imprint: Madrid, M. González.

Bulletin de la Société nationale d'acclimatation et de protection de la nature de France.

Vols. for 1930-1941 include: Actes de la Réserve zoologique et botanique de Camargue, no. 1-24.

Affaire du mois d'avril 1834.

Vol. 8 wanting in L. C. set. Vols. 1-6, 9, 13-15 lettered: Cour de pairs. v. 1-5, 7, 6, 8-10. Affaire d'avril 1834; v. 7, 10-12 lettered: Cour des pairs. Affaire d'avril 1834. [v] 1, 3-5.

Dictionnaire universel d'agriculture et de jardinage : de fauconnerie, chasse, pêche, cuisine et manége, en deux parties.

Goldsmiths'-Kress no. 08603.5.

D. Bvrcard. Gotthelf Strvvii ... Ivrisprvdentia heroica, sev Ivs qvo illvstres vtvntvr privatvm, ex innvmeris exemplis actis pvblicis editis et ineditis atqve historiarvm monvmentis omnis aevi illvstratvm.

Three additional volumes projected were never published. cf. Prefatory remarks to vol. VII.

Bibliothèque américaine, contenant des mémoires sur l'agriculture, le commerce, les manufactures, les moeurs et les usages de l'Amérique; l'analyse des ouvrages scientifiques de ce pays, ainsi que de ceux des Européens qui y ont voyagé; et des extraits des journaux publiés en Amérique, sur tout ce qui peut intéresser le commerc̜ant et l'homme d'état; par une sociéte de savans et d'hommes de lettres ...

Collation: [no. 1-2] 195 p. 6 fold. tab.-[no. 3] 123 p.-[no. 4] 127 p.-[no. 5] 131 p.-[no. 6] p. [133]-244.-[no. 7] 140 p.-[no. 8] p. [141]-256-[no. 9] p. [257]-384.

Storia generale d'Italia,

In v. 3-5 and 7 the general title reads "Storia politica d'Italia ..." Vol. 8 has only special title with added t. p.

Revue internationale d'apiculture.

Editor: 1879-1903, Edouard Bertrand.

Mémoires militaires relatifs à la succession d'Espagne sous Louis XIV, extraits de la correspondance de la cour et des généraux par le lieutenant général de Vault ...

Atlas issued in eight parts (pt. [1-6] each with separate t.-p.) 1836-[62]

Catalogue des collections d'antiquités au château de Heeswijk. Musée "Baron van den Bogaerde" ... La vente aura lieu à Bois-le-duc dans la salle du "Casino" ...1899[-1901]

[Partie] 1. La salle d'armes.--[Partie] 2. Galerie de portraits et autres tableaux anciens.--[Partie] 3. Meubles, bronzes, marbres, porcelaines, argenterie, objets en or, etc.--[Partie] 4-5. Art religieux, tableaux, sculptures, broderie, orfèvrerie, etc.; arts du métal, ferronnerie serrurerie, dinanderie, étain.--[Partie] 6. Antiquités diverses, portraits peints, miniatures, sculptures en marbre, meubles, montres...etc.--Partie 7. Collections des châteaux de Heeswijk et de Haren.

Revue d'anthropologie.

Issues for sér. 2-3 also numbered as 7.-18. année.

Mémoires du général Bon Thiébault, pub. sous les auspices de Claire Thiébault, d'après le manuscrit original,

Vol. 1: 6 éd.

Suboptimal Vitamin D Associated with Dental Caries at an Urban Pediatric Hospital

Thesis (Master's)--University of Washington, 2016-06

The role of morphine-6-glucuronide (M6G) in pain control

Morphine-6beta-D-glucuronide (M6G) is an analgesically active metabolite of morphine, accounting for approximate to10% of the morphine dose when administered by systemic routes to humans. Although M6G is more hydrophilic than morphine, it crosses the blood-brain barrier, albeit relatively slowly. For this reason, it is generally thought that, after chronic dosing, M6G contributes significantly to the analgesic effects of systemically administered morphine. Owing to its polar nature, M6G is cleared from the systemic circulation primarily via renal elimination. As M6G accumulates in patients with renal impairment, there is an increased risk of M6G-induced respiratory depression in renal failure patients who are being dosed chronically with systemic morphine. Consistent with its analgesic and respiratory depressant properties, M6G binds to the p-opioid receptor in a naloxone-reversible manner. Although the affinity of M6G for the mu-opioid receptor is similar to or slightly less than that of morphine, preclinical studies in rodents show that M6G is one to two orders of magnitude more potent than morphine when administered by central routes. This major discrepancy between the markedly higher intrinsic antinociceptive potency of M6G relative to morphine, despite their similar p-opioid receptor binding affinities, is difficult to reconcile. It has been proposed that M6G mediates its pain-relieving effects through a novel 'M6G opioid receptor', while others have argued that M6G may have higher efficacy than morphine for transduction of intracellular events. When administered by parenteral routes to rodents, M6G's antinociceptive potency is no more than twofold higher than morphine. In humans, the analgesic efficacy and respiratory depressant potency of M6G relative to morphine have been assessed in a number of short-term studies involving the intrathecal or intravenous routes of administration. For example, in hip replacement patients, intrathecal M6G provided excellent postoperative analgesia but the occurrence of late respiratory depression in 10% of these patients raised serious concern about safety. In postoperative patients, intravenous M6G administered by means of patient-controlled analgesia (PCA), or bolus plus PCA, produced no analgesia in one study and limited analgesia in another. Similarly, there was a lack of significant analgesia in healthy volunteers who received intravenous M6G for the alleviation of experimental pain (carbon dioxide applied to the nasal mucosa). In contrast, satisfactory analgesia was produced by bolus doses of intravenous M6G administered to patients with cancer pain, and to healthy volunteers with experimentally-induced ischaemic, electrical or thermal (ice water) pain. Studies to date in healthy volunteers suggest that intravenous M6G may be a less potent respiratory depressant and have a lower propensity for producing nausea and vomiting than morphine. However, it is unclear whether equi-analgesic doses of M6G and morphine were compared. Clearly, more extensive short-term trials, together with studies involving chronic M6G administration, are necessary before the potential clinical utility of M6G as an analgesic drug in its own right can be determined.

Enzymatic cyclization of a potent Bowman-Birk protease inhibitor, sunflower trypsin inhibitor-1, and solution structure of an acyclic precursor peptide

The most potent known naturally occurring Bowman-Birk inhibitor, sunflower trypsin inhibitor-1 (SFTI-1), is a bicyclic 14-amino acid peptide from sunflower seeds comprising one disulfide bond and a cyclic backbone. At present, little is known about the cyclization mechanism of SFTI-1. We show here that an acyclic permutant of SFTI-1 open at its scissile bond, SFTI-1[ 6,5], also functions as an inhibitor of trypsin and that it can be enzymatically backbone-cyclized by incubation with bovine beta-trypsin. The resulting ratio of cyclic SFTI-1 to SFTI1[6,5] is similar to9:1 regardless of whether trypsin is incubated with SFTI-1[ 6,5] or SFTI-1. Enzymatic resynthesis of the scissile bond to form cyclic SFTI-1 is a novel mechanism of cyclization of SFTI-1[ 6,5]. Such a reaction could potentially occur on a trypsin affinity column as used in the original isolation procedure of SFTI-1. We therefore extracted SFTI-1 from sunflower seeds without a trypsin purification step and confirmed that the backbone of SFTI-1 is indeed naturally cyclic. Structural studies on SFTI-1[ 6,5] revealed high heterogeneity, and multiple species of SFTI-1[ 6,5] were identified. The main species closely resembles the structure of cyclic SFTI-1 with the broken binding loop able to rotate between a cis/trans geometry of the I7-P8 bond with the cis conformer being similar to the canonical binding loop conformation. The non-reactive loop adopts a beta-hairpin structure as in cyclic wild-type SFTI-1. Another species exhibits an isoaspartate residue at position 14 and provides implications for possible in vivo cyclization mechanisms.